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Artemisinin-Based Combination Therapy (ACTs) Drug Resistance Trends in
Plasmodium falciparum Isolates in Southeast Asia

Jessica L. Schilke
ABSTRACT
Plasmodium falciparum, one of the parasites that cause clinical malaria, is a
continuous public health concern, especially in Asia and Africa. Unfortunately, the
parasite has developed resistance to many drugs created to treat and prevent the disease.
Artemisinin and its derivatives are the new gold standard for treatment of malaria,
yet treatment failures in clinical studies are starting to be reported. Clearly, artemisinin
resistance needs to be characterized and dealt with accordingly. In support of the Gates
Foundation Artemisinin Consortium, we conducted a blinded study to elucidate the
phenotypic response of artemisinin derivatives of parasites derived from patient blood
samples from Cambodia and Thailand. Blood samples containing Plasmodium
falciparum were cultured and then assayed using SYBR green as an indicator to obtain
drug IC50s. The data suggested that many isolates are not demonstrating resistance to
artemisinin. However, a select few are showing some resistant characteristics in the form
of elevated IC 50s, especially to some of the drugs already identified in previous studies
as drugs having resistant characteristics. Compared to studies conducted within the past
ten years, no significant changes in parasite susceptibility to the artemisinin drugs have
vi

been observed. Additional analysis of clinical outcomes, therapeutic drug levels, and
molecular markers needs to be completed before it can be assumed that artemisinin
resistance has emerged.
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Introduction
Malaria
Malaria is one of the most problematic tropical diseases worldwide. Endemic to
Parts of South and Central America, Africa, and Southeast Asia, half of the world is at
risk for contracting malaria. It’s responsible for over 300 million illnesses per year and
an estimated three million mortalities (WHO, 2008). One malaria related death occurs
approximately every 30 seconds, mainly in children and pregnant women. Malaria is
caused by a parasite in the genus Plasmodium, and five different species affecting
humans have been discovered thus far. Of those five species, Plasmodium falciparum by
far causes the most morbidity and mortality. There is no vaccine for malaria, but there
are treatment options available. Unfortunately, drug resistance has rapidly become a
major issue in controlling malaria, and has been identified in both Plasmodium faciparum
and Plasmodium vivax (CDC, 2008). This thesis attempts to classify some of the
resistance trends to some currently common treatment options in Southeast Asia,
specifically in Thailand and Cambodia.
Life Cycle
The definitive host of the malaria parasite is the female anopheline mosquito
(John, 2006). The female mosquito takes a blood meal, and injects sporozoites located in
her salivary glands into her host (see Figure 1). These sporozoites then travel from the
bloodstream to hepatocytes. Asexual reproduction (schizogony) then occurs in the liver.
1

Schizogony occurs immediately in P. falciparum, and results in the formation of
merozoites, which move into the blood stream due to the rupturing of hepatocytes. The
merozoites invade RBCs, and erythrocytic schizogony follow, producing anywhere from
2 to 36 merozoites per infected red blood cell. The erythrocyte eventually ruptures,
releasing more merozoites into the blood stream. Usually after the patient becomes ill,
some of the merozoites form male and female gametocytes, which can then be taken up
by the mosquito during the blood meal process. Once in the mosquito stomach, these
gametocytes mature into micro and macrogametes. The male microgamete is then
capable of fertilizing the female macrogamete, which forms into an ookinate. The
ookinate then becomes an oocyst just outside of the mosquito’s stomach. The oocyst
produces sporozoites, which can detach and find their way into the salivary glands of the
mosquito. The sporozoites are then injected into the mosquito’s host when the female
mosquito takes a blood meal. This thesis examines the asexual erythrocytic stages of
Plasmodium falciparum in vitro under drug pressure.
Clinical features
Plasmodium falciparum is the malaria species that causes the most morbidity and
mortality in humans. The incubation period in the body is the shortest, only about 8-11
days, and if left untreated, could last anywhere from 6-17 months. Fever in P. falciparum
can be ‘continuous, remittent or quotidian” (John, 2006). Prodromal symptoms include
aches and pains, photophobia, nausea and even vomiting. The paroxysm stage begins
with the symptoms of feeling severely cold, even though fever is present. Ten to fifteen
minutes later, the patient begins to feels extremely warm and becomes flushed and
agitated. Restlessness and delirium can also accompany this stage. This can last hours
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and is followed by a sweating phase. The paroxysm stage in P. falciparum patients can
occur mere hours after the previous episode. Other symptoms include splenomegaly,
anemia, capillary obstruction, decreased blood flow, hypoxia, renal failure and even
death in cases of cerebral malaria.
Blackwater fever is yet another complication of P. falciparum, which occurs from
severe hemolysis within the patient’s veins and is usually associated with the use of
quinine (Rieckmann, 2006). Other less common complications include Dysenteric
Malaria, Algid Malaria, Pulmonary Edema, Tropical Splenomegaly Syndrome and
Hypoglycemia. Pathogenesis in humans is caused by a variety of factors, including
hemolysis of red blood cells, red blood cells sticking to the endothelial cells of the
vascular system and decreasing blood flow, the patient’s own immune response, parasite
metabolites released into the body, as well as the malaria pigment (Rieckman, 2006).
Artemisinin
Artemisinin is a lactone derived from the leaves of Artemisia annua, or sweet
wormwood. It is also known to the Chinese as qinghao, and has been used to treat
ailments such as hemorrhoids and fever for over a thousand years. China’s government
later decided to try to join traditional Chinese medicine with western medicine, and a
program to screen traditional Chinese remedies for activity began in 1967.
It was first proposed that the mechanism of action of artemisinin was due to the
endoperoxide bridge, which generates free radicals. It has been thought that the malaria
parasite has been susceptible to free radicals. To test the theory that free radicals were
involved in the mechanism of action, tests were conducted in the 1980s and it is was
found that free radical generators promoted the activity of artemisinin against malaria,
3

and free radical scavengers were found to inhibit the activity. Free radicals were also
found to inhibit a calcium adenosine triphoshatase PfATPase 6 (Sherman, 1998).
Artemisinin is active against the blood schizont stage of the malaria parasite, and reduces
parasite load in all malaria species.

It is unique in that it is effective in killing all

asexual blood stages of the malaria parasite as well as gametocytes in P. falciparum.
Before artemisinin was discovered, the only drug that killed gametocytes was
primaquine. The highest drug concentrations in the plasma occur around 3 hours when
administered orally, and around 11 hours when given in a suppository form. It has a
molecular weight of 282.3; the elimination half life is around 1 hour. Finally, it is
converted into inactive metabolites via enzymes including cytochrome P450 and
CYP2B6.
Side effects include dizziness, gastrointestinal problems, reticulocytopenia,
neutropenia, and infrequently electrocardiographic abnormalities. However, the
artemisinin drugs do not cause nearly as many side effects in humans as some of the other
antimalarials, and there are currently no known drug interactions, making it an almost
ideal treatment option. One in 3000 patients report hypersensitivity reactions, which is
the only serious side effect reported.
The recommended use of artemisinin, as well its derivatives, artemether,
artemotil, artelinic acid, dihydroartemisinin, artemether and artesunate, is in combination
with other antimalarials in order to reduce the potential emergence of resistance (WHO,
2006).
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Artemether
The methyl ether form of dihydroartemisinin is artemether. With a molecular
weight of 298.4, peak concentrations of drug in the plasma occur around two to three
hours after it is taken orally. It can also be introduced into the body by being injected
directly into the muscle of the patient, but this method causes extreme variability in
absorption amount, with peak times ranging from 6 to over 18 hours. However, when
injected, artemether itself is the predominate form of the drug, whereas when
administered orally, dihydroartemisinin is the artemisinin derivative found most readily
throughout the body. The elimination half life is about 1 hour when given orally but can
be longer when injected. Biotransformation occurs via CYP3A4, a cytochrome p40
enzyme.
Side effects are very similar to artemisinin, however, it was found in animals to
cause damage to the neurons when given intramuscularly. This is due to the fact that
high concentrations of drug are within the blood when given in this manner. There are
also no known drug interactions with artemether.
Artesunate
The sodium salt of the hemisuccinate ester of artemisinin is artesunate. It is water
soluble, and can be administered orally, intravenously, as well as rectally. Peak plasma
levels happen at around 1.5 hours after oral administration, 2 hours after given rectally,
and one half hour after given intramuscularly. The form found most frequently in the
body is dihydroartemisinin. Toxicity is again similar to artemisinin, and there are no
currently known drug interactions.
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Dihydroartemisinin
An active metabolite of artemisinin is known as dihydroartemisinin. It can be
given both in oral and rectal forms, and its effectiveness can be compared to oral
administration of artesunate. Peak plasma levels occur at around 2.5 hours when given
orally, and slightly slower (around four hours) when given rectally. Toxicity is similar to
that of artemisinin and there are no currently known drug interactions.
Artemisinin Combination Drugs (ACTs)
Lumefantrine
Lumefantrine is a drug that is co administered orally with artemether. It needs to
be consumed with fatty foods which increases absorption by 108%. Highest levels in the
plasma occur at around 10 hours after administering. There is no toxicity reported with
lumefantrine, and the only side effects reported include headache, dizziness, nausea, and
discomfort of the abdomen. It has a molecular weight of 528.9.
Atovaquone
Atovaquone is a drug that is known to interfere with the electron transport chain
of the parasite. It is effective against all Plasmodium species, and also inhibits oocyst
development within the mosquito, as well as development in the liver before it invades
red blood cells. It is has been available since the early 1990s in combination with
proguanil in tablet form (Malarone). Similar to lumefantrine, absorption is increased
when taken with food. The half life is around 66-70 hours due to enter hepatic recycling,
however pregnancy can reduce its half life.
Mild side effects reported include diarrhea, vomiting, insomnia, skin rash, fever,
increased liver enzymes, and sometimes anemia and neutropenia. When administered to
6

patients taking drugs such as tetracycline, metoclopramide, as well as benzodiazepines,
cephalosporins, laxatives, opiods and paracetamol, reduced concentrations in the plasma
may occur. It also decreases metabolism of the drugs zidovudine and cotrimoxazole.
Atovaquone/proguanil (Malarone) is usually successful after a three day course, however
it is not widely used due it its high costs. (Rieckman, 2008). It can also be used as a
prophylactic for travelers and military personnel. Malarone is also used to treat travelers
not endemic to malarias areas, and is approved for use in North America and Europe
(CDC, 2008). Studies examining patient isolates along the Thai-Myanmar and ThaiCambodia border have shown that resistance to atovaquone is not yet an issue. It has,
however, been reported that the point mutation on codon 268 on the cytochrome B gene
is responsible for treatment failures that have thus far been reported (Khositnithikul,
2008). This point mutation is key in identifying atovaquone resistant blood isolates.
Mefloquine
Mefloquine is effective against all Plasmodium species and came about as a result
of screening a massive amount of drugs for antimalarial activity during the 1960s
(Reichmann, 2008). It is a 4-methanolquinoline related to quinine, and is given orally as
the hydrochloride salt. It is given both as a prophylactic to travelers, as well as a disease
treatment. It is only slightly water soluble, but is completely soluble in alcohol. Since
mefloquine has varying time to achieve peak levels in the plasma, it is administered in
two separate oral doses 6-24 hours apart in order to improve absorption. Enterohepatic
recycling occurs with mefloquine. It can be co administered with artesunate, which
increases concentrations in the blood. Unfortunately, side effects are common, including
nausea vomiting diarrhea anorexia, abdominal pain, headache, dizziness, dysphoria and
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various sleep disturbances such as insomnia and strange dreams. Less commonly,
seizures, encephalopathy and psychosis can occur, as well as the occasional case of hair
loss, skin rash, purities, muscle weakness and problems with liver function. Some
cardiovascular effects have also occurred when mefloquine was given. There are also
possible risks of drug interactions. These include arrhythmias when taken with beta
blockers, calcium channel blockers, amiodarone, pimozide, digoxin or antidepressants.
When taken with chloroquine or quinine, convulsion risk is possible as well. In order to
minimize recrudescence and due it its low half life and ability to clear parasites,
mefloquine is given in combination with artesunate. Unfortunately, some cross
resistance between mefloquine and artesunate has been reported in Thailand, as well as
mefloquine resistance (Wongsrichanalai, 1999). Researchers have identified an
amplification of the gene pfmdr1 that has been linked to mefloquine resistance (Price,
2004).
Piperiquine
Piperiquine, otherwise known as bischloroquine, is given in combination with
dihydroartemisinin to treat uncomplicated malaria. Piperiquine has a long half life, so it
not only able to treat uncomplicated malaria, but also to provide protection for
reoccurrence. The side effects are minimal, and the combination drug is inexpensive to
dispense. (Tran, 2004)
Anti-malarial Drug Resistance Patterns
Most of the drug resistance towards anti-malarials was first documented and
reported along the south-eastern border of Thailand and Cambodia. For example,
resistance began here in the 1950s to chloroquine, followed by the anti-malarials
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sulfadoxine-pyrimethamine and mefloquine. This is why the isolates collected were
chosen from this location. Drugs that were once “gold standards” to effectively treat
patients infected with malaria are now almost completely ineffective, the origins of
resistance being in Southeast Asia. Therefore, newer drug classes are being developed in
order to stay one step ahead of the parasite.
The World Health Organization has made ACTs the most widely used and
effective drugs worldwide (CDC.gov). A drug combination of mefloquine and artesunate
has replaced all previous drugs and been the main treatment prescribed ever since 1995.
However recently, failure rates with artemisinin drugs in the clinic have been reported,
specifically along the Thai-Cambodian border. If resistance truly is occurring, control
measures must be started in order to characterize and contain the resistance so that it does
not become widespread, as in the case of past gold standard malarial treatments.
First, it is important to discern between drug resistance and “treatment failure”.
Drug resistance is defined as “the ability of a parasite strain to survive, and/or multiply
despite the proper administration and absorption of an antimalarial drug in the dose
normally recommended” (Sherman, 1998). Treatment failure, on the other hand, is
“failure to clear malarial parasitemia and/or resolve clinical symptoms despite the
administration of antimalarials (Sherman, 1998). It also needs to be understood that drug
resistance can indeed lead to treatment failure. However, treatment failures can be
caused by phenomenons other than drug resistance, including administering the incorrect
dose and/or drug, compliance, drug quality not being up to standards, drug-drug
interactions, issues with absorption of the drug, and incorrect diagnoses. In order to
combat some of these issues with malaria treatment that could lead to failure and possibly
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resistance, the “Roll Back Malaria” strategy has been created in order to enforce proper
compliance with treatment (Ikeoluwapo, 2008). At least 18 countries in Africa have
adopted this strategy, and 44 countries in Africa are now using artemisinin combination
therapies (ACTs) as a first choice to treat uncomplicated malaria. Enforcing proper use
of ACTs isn’t as much of an issue in healthcare facilities as it is on a community level,
which facilities drug failure and resistance. Counterfeit treatments which do not contain
the correct dose also tend to leak into communities, facilitating resistance.
Drug resistant malaria strains can arise in a variety of ways. The first event
leading to resistance involves a change in the parasites genetic code, following by a
process of selection that allows the new resistance mutants to survive and take over as the
dominant parasite (Sherman, 2008). Factors that assist in resistance development include
the amount of genetic mutations that are occurring in a certain region and the number of
parasites that are exposed to the drug. In addition, the amount of immunity in an
individual with the disease under drug pressure and the pharmacokinetics are also
involved in resistance (Sherman, 2008). Therefore, it is imperative to administer the
correct amount of drug needed to kill the parasite, so that the strongest parasites aren’t the
only ones that survive and multiply. Again, antimalarial drug distribution and dosing
isn’t always properly regimented in some areas of the world. Thus, these issues
commonly arise. Since lumefantrine, atovaquone and mefloquine are absorbed at varying
rates due to their lipophilic properties, they are more prone to resistance, since the peak
drug concentrations rely heavily on absorption.
Unfortunately, for reasons still unknown, one of the main issues with the
artemisinin drugs is the tendency for patients to recrudesce (Giao, 2001). One to four
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weeks after being treated with an artemisinin drug, 10%-40% of patients experience
recrudescence. Parasites can become undetectable after a single day of artemisinin
therapy, but patients can recrudesce if not repeated treated. One attempt to decrease the
risk for resistance includes giving antimalarials in combination forms. The hope here is
that the drugs have unique mechanisms of actions and therefore the way that resistance
would arise would vary. This issue of recrudescence is also cause for alarm when
looking at ACT resistance rates, and discerning between the recrudescent infections of P.
falciparum and actual resistant strains. In addition, the short half life of artemisinin
makes it more difficult to monitor proper administration of the drug to patients, which
could also lead to more unclassified resistance. All of these issues combined could
possible lead to widespread artemisinin resistance.
ACT resistance studies
Due to the unusually high incidence of drug resistance in Thailand and Cambodia,
and some high clearance and treatment failure rates that were being clinically reported
with some ACT use, studies were conducted to examine patient susceptibility to current
ACTs. The Army component of the U.S. Armed Forces Research Institute of Medical
Sciences conducted two studies in 2005 and 2006 to determine if drug resistance was the
culprit to these clinical failures. The first studies led to a conclusion that 16.6% of
patients failed therapy when given a drug combination of mefloquine and artesunate
(Penh, 2007). A second study was then conducted administering artesunate alone. In
vitro results showed artemisinin IC50s were higher along the Thai-Cambodian border,
versus other areas where the same treatment was administered. A conclusion was made
that preliminary evidence had been gathered that artemisinin resistance had emerged
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along the Thai-Cambodian border. Recently, another study was published in the New
England Journal of Medicine that revealed out of 60 people receiving artesunate
treatment, two were classified as having an artemisinin resistant infection (Noedl, 2008).
Although this is a small amount of people, it is still concerning, as resistance can spread
rapidly if not contained. The most concerning data from this study was the prolonged
clearance times for parasitemia, which significantly increased for all previous studies of
ACTs.
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Purpose
The purpose of this thesis was to culture and then conduct blinded phenotypic
analyses to identify possible ACT susceptibility trends in isolates infected with
Plasmodium faciparum from regions in both Thailand and Cambodia. These trends were
observed both for single drugs, as well as in combination form. Plasmodium falciparum
isolates also were cultured and frozen for use in future ACT resistance experiments.
Characterization of drug resistance is key in order to control the spread of the disease,
containment of resistance, as well as successful treatment of the malaria parasite.
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Figure 1: Life Cycle of Plasmodium falciparum
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Figure 2: Chemical Structures of the 8 Compounds Tested
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Methods
Obtaining samples
Isolate samples were collected from both Maesod in Thailand and Palan on the
Thai-Cambodian border, cryopreserved and shipped to the University of South Florida in
Tampa. Reference strains C2B, W2 and D6 were used in this experiment in order to
compare the blind isolate data. C2B is a P. falciparum strain that is resistant to
atovaquone, due to a point mutation in cytochrome B. W2, a strain isolated from
IndoChina, is historically chloroquine resistant and mefloquine sensitive. Lastly D6, a
strain isolated from Sierra Leonne, is historically chloroquine sensitive and naturally
mefloquine resistant.
Thawing of Field Isolate Samples
Each blood sample vial was wiped down with 70% Ethanol to sterilize, and then
thawed in a 37°C water bath for 2 minutes. The sample was then transferred into a 50 ml
sterile centrifuge tube and 0.1% of 12% sterile NaCl of the volume of the isolate sample
was added drop wise to the sample, swirling the sample between each drop addition. The
sample containing the 12% NaCl was then allowed to sit untouched for five minutes,
followed by the addition of ten times of 1.6% sterile NaCl of the new isolate volume
(isolate plus volume of 12% NaCl added). The NaCl was added drop wise for the first ml
with swirling between each drop, followed by swirling after each 0.5 ml addition of 1.6%
NaCl. The sample was then centrifuged at 4,000 rpm at 4°C for 2 minutes. Next, the
supernatant was aspirated off of the isolate, leaving a small amount above the hematocrit,
16

with taken not to remove any parasites. The pellet was then resuspended in 10 ml of
RMPI with HEPES, and centrifuged again at 4,000 rpm at 4° C for 2 minutes. The
supernatant was aspirated, again leaving a small amount above the pellet, then resuspended in 10ml of complete media containing 15% heat-inactivated AB plasma. In
the third round of isolate thawing, the complete media was supplemented with 10ul/1ml
of penicillin/neomycin/streptomycin solution in order to reduce bacterial contamination.
The suspension was then centrifuged at 4,000 rpm at 4° C for 2 minutes, and the
supernatant removed once more as noted previously. The pellet was then resuspended in
10 ml RPMI with HEPES, and again centrifuged at 4,000 rpm at 4°C for 2 minutes. The
supernatant was aspirated again, and the pellet resuspended in 2ml of complete media
containing 15% AB plasma. 50ul of the suspension was added drop wise to filter paper
and left to air dry for future studies of molecular markers. If red blood cell lyses was
observed, 15-30 ul of 50% hematocrit O (+) blood was added to the suspension prior to
incubating the culture. The suspension was then transferred into a six well plate, placed
in a modulator incubator, air displaced with mixed gas (5%O2/5%CO2/90%N), and
incubated at 37° C.
Culturing
Incubator modulators containing the six-well plates were gassed every twenty
four hours with mixed gas. Twenty four hours after initially thawing the isolates, the sixwell plate was removed from the incubator and tipped at a 45° angle to allow the
hematocrit to settle in order to make slides. 5ul of hematocrit was removed to make both
a thin and thick smear. Slides were made initially every day to check for growth of both
the parasite and contamination. O+ blood was continuously added to each well to keep
17

the isolate up to 4% hematocrit while in the six-well plates. Contamination was
contained by spinning the isolate in a 15 ml falcon tube at 4,000 rpm at 4° C for 2
minutes, followed by removing the supernatant. The remaining pellet was then
resuspended in 2 ml fresh complete media containing 15% AB plasma, as well as
penicillin/streptomycin/neomycin [5,000U/5mg/10mg] at a concentration of 2ul/ml. Each
isolate was treated every day until contamination was no longer seen in the thick smear.
Slides were made less frequently (every 2-4 days) when no initial parasites were
observed. When 2% parasitemia was observed in an isolate thin smear, the isolate was
centrifuged for 2 minutes at 37° C at 4000 rpm, and the old media removed. The parasite
was then resuspended in 5 ml 10% CM at 4% hematocrit (O+ blood) and transferred into
a tissue culture flask. The flask was then incubated at 37° C with the carbon dioxide,
nitrogen and oxygen mixture used previously. Media was replaced with fresh 10% AB
plasma every day, and both thin and thick smears were made, until the parasitemia
reached 3%, and at least 40% ring stage was observed. The flask was then split into two,
and the remaining blood pellet was frozen down for stock. These flasks were then
checked every day until 3% parasitemia was observed. At this point one flask was split
again to continue growth, and the other flask was used for the drug assay. At least four
cryopreserved vials of each isolate were frozen in total for stock and future use.
Freezing Protocol
When the isolate was at least 40% rings and 3% parasitemia, they were frozen for
future ACT resistance characterization studies. The culture was centrifuged at 4,000 rpm
for 15 minutes at 4°C, and the supernatant removed. Glycerolyte 57 (57g glycerin, 1.6 g
sodium lactate, 30 mg potassium chloride, buffered with 51.7 mg monobasic sodium
18

phosphate and 124,2 dibasic sodium phosphate, pH 6.8.) was added slowly drop wise to
the pellet at 0.33 times that volume of the isolate pellet. The sample was then allowed to
stand for five minutes, and Glycerolyte 57 was added again drop wise at 1.33 times the
volume of the original isolate pellet and the first Glycerolyte 57 addition. The sample
was then transferred into a cryovial and stored at -80° C for future resistance
experiments.
Plasma, Media, and Blood Preparation
O+ RBCs were used when culturing and assaying each isolate. Blood was
suspended in RPMI 1640 plus HEPES containing sodium bicarbonate, and centrifuged at
4000 g, 37° C for 15 minutes. The supernatant and buffy coat were removed, and the
remaining blood was re-suspended in the (RPMI/HEPES/sodium bicarbonate) wash and
centrifuged three more times. The supernatant was removed in between each wash and
the blood was resuspended in RPMI wash media, at five, five, and fifteen minute
increments. After the supernatant was removed the final time, the remaining hematocrit
was diluted to 50% in the RBC wash media, and stored at -40° C for up to one week
before new 50% hematocrit was prepared.
Plasma for cell culture media was provided by Interstate Blood Bank. Plasma
was allowed to warm to 60° C for one hour with gentle agitation. The plasma was then
cooled at room temperature for 15 minutes, then refrigerated at -40°C for an additional 15
minutes. Plasma was then transferred into 50 ml falcon tubes, and centrifuged for 15
minutes, at 4000 rpm for 15 minutes. The plasma lots were then pooled and frozen at 80° C. Before use, plasma was thawed in a 37° C water bath.
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Slide Preparation
A 5ul aliquot of the isolate sample was taken from culture, and 1ul was dispensed
by smearing in a circler fashion on one part of the slide for the “thick smear,” and the
remaining 4ul was dispensed on the other side of the slide for the thin smear. A separate
clean slide was used to spread a thin layer of cells across the second half of the slide. The
sample was allowed to dry, and the “thin smear” was dipped in methanol and again
allowed to dry. 15% or 20% Giemsa stain was then dropped onto the slide, and the slides
were then rinsed with water after a period of 10-20 minutes. The slides were then dried
and ready to be examined.
Drug Assay Preparations
Drug “mother” plates were prepared using the Biomek 3000 robot. Drugs in the
mother plates were all prepared at 10 times the final concentration to be used in the final
assay “daughter” plate. Initially, drug stock solution was prepared at a concentration of 1
mg/ml and dissolved in DMSO. Next, drugs were diluted down to ten times the desired
concentration in 10% AB plasma complete media, and 300 ul of each suspension was
added to the first row of a 96 well mother plate. The drugs then underwent a 1:2 dilution
scheme to complete the “mother plate.” This plate was used up to 5 times to make the
‘daughter plates”, which contained both the drug as well as the parasites. This dilution
scheme reduced the final DMSO concentration to less than 1%.
Isolate Suspension for Assay:
Once each isolate was grown to a least 3% parasitemia, and greater than 40%
rings, each isolate culture was prepared for the drug assay. First, the cells were
centrifuged at 4000 g at 37° C for 5 minutes. Complete media containing 10% AB
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plasma was prepared, and 1.5% total hematocrit was added to the media, with a
parasitemia of 0.5%. The suspension was gently mixed before added to the daughter
assay plate. 15 ul of the “mother plate” drug suspensions was transferred to each
corresponding “daughter” well by the Biomek robot, and 150 ul of cell suspension was
then added to each well. 25 mg/ml of each artemisinin and dihydroartemisinin were
added directly in duplicate form to serve as negative controls. The parasite suspension
without the addition of any drug served as the positive controls in the plate. Finally, the
plates were placed in a modulator incubator and incubated for 72 hours at 37° C. The
incubator was gassed every 24 hours (5%O2/5%CO2/90%N). After 72 hours, plates
were wrapped in foil to protect from light, and placed in a -80°C freezer until the SYBR
green assay was ready to be performed.
SYBR Green Assay
Drug plates containing lysed isolates were assayed via a fluorescent based SYBR
Green assay, a quick and easier method of finding the IC50 values than alternate
methods. (Bacon, 2006) Plates were thawed for two hours after being frozen in a -80° C
freezer overnight. Then,100 ul of parasite suspension was transferred into a black 96
well plate compatible with the plate reader. The 100 ul of SYBR Green I in lyses buffer
containing Tris 20 nM (Ph 7.5), EDTA (5mM), saponin (0.008% wt/vol and Triton X100 (0.08% wt/vol) was also added to the wells containing the thawed parasites in the
drug assay plate. The plates were then immediately allowed to incubate light free for one
hour before read. The intensity of the florescence was measured using the SpectraMaxM2 plate reader, with an excitation wavelength of 485 nm and an emission wavelength of
535 nm.
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Isobologram Assay
Three isolates that showed the highest resistance to the 8 compounds overall were
chosen to perform a drug combination assay. Starting plate concentrations for each drug
were calculated by using the IC50 value calculated in the single compound assay. The
starting drug IC50s were chosen in order for the IC50s in the multi drug plate to
hypothetically be the original starting concentration in the plate if the assay was redone.
The plate design consisted of a row of each of the drug pairs alone, followed by the pairs
in ratios on 1:3, 1:1 and 3:1. The drug pairs tested consisted of either QHS or DHA,
depending on which one the isolate was showing the least susceptibility to. These drugs
were paired with MFQ and PIP, both commonly administered drug combinations in the
clinic.
Thai isolate 18, 6, and Cambodia isolate 6 were used in the isobologram assay
plates. W2 was used as a control. The starting concentrations in the assay plate of Thai
18 were 8.7 ng/ml for DHA, 234.2 ng/ml for MFQ and 179.9 ng/ml for PIP. Thai 6 had
starting drug concentrations of 80 ng/ml for QHS, 175.1 ng/ml for MFQ, and 163.9
ng/ml for PIP. Cambodia isolate 6 had starting concentrations of 6.1 ng/ml for QHS, 56
ng/ml for MFQ and 12.36 ng/ml for PIP. Reference clone W2 had a starting
concentration of 11.88 ng/ml for QHS, 30.22 ng/ml for MFQ, 225.25 ng/ml for PIP and
4.9 ng/ml for DHA.
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Data Analysis
Linear and non-linear regression curves for IC50s, IC90s and FIC isobologram
curves were calculating using DatAspects Plate Manager (DPM) software. Data was
imported into the software from the plate reader using the Biotec format. Relative
Fluorescent Units (RFUs) were converted into percent inhibition in the program.
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Figure 3: Map Depicting Isolate Collection Sites
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Figure 4: 6 Well Plates Containing Isolates
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Figure 5: Isolates Growing Within Tissue Culture Flasks
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Figure 6 : Geimsa Staining of Isolates
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Figure 7: 96 Well Drug Assay Plate Set Up
(D
Drug Name and Concentration in ng/ml)
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Figure 8: Biomek 3000 “Robot” Used to Complete Drug Assays
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Figure 9: Plate Reader for SYBR Green Assay
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Figure 10: Incubator Modulators Containing 6 Well Plates (Right) and 96
Well Assay Plates (Left)
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Results
Cell Culture Success
A total of 66 isolates, 42 Cambodia, 24 Thai, were thawed. Out of the 42
Cambodia isolates, 19 grew enough to be assayed (45%). Out of the 24 Thai isolates
thawed, 15 grow well enough to be assayed (63%). Overall, a growth success rate of
52% was obtained. The addition of antibiotic to the complete media during the thawing
process noticeably increased the percentage of isolates that successfully grew. For
instance, a 50% growth success rate was obtained before the antibiotic was added during
the thawing process, and a 56% growth rate was obtained after the antibiotic was added.
Contamination was also greatly reduced overall when the antibiotic was added during the
thawing process. Before antibiotic was added, at least 50% of samples showed some
degree of bacterial contamination, both rods and cocci, versus around 5% after antibiotic
was added.
Single Drug Assay Data
The IC50s (in nmol/l) varied between isolates, depending on type of drug pressure
(refer to tables 1 and 2, as well as Appendix B). IC50s of isolates exposed to artemether
ranged from 0.7 to 10.3 nmol/l. IC50s of isolates exposed to artesunate ranged from 0.2
to 6.4 nmol/l. IC50s of isolates exposed to atovaquone ranged from 0.2 to 13.9 nmol/l.
IC50s of isolates exposed to dihydroartemisinin ranged from 0.4 to 7.1 nmol/l. IC50s of
isolates exposed to lumefantrine ranged from 6.5 to 395.3nmol/l. IC50s of isolates
exposed to mefloquine ranged from 2 to 135.1 nmol/l. IC50s of exposed to piperaquine
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ranged from 4.7 to 124.1 nmol/l. IC50s of isolates exposed to Artemisinin ranged from
1.4 to 35.4nmol/l.
Certain isolates, both Thai and Cambodian, consistently produced high IC50s in
the standard 72 hours drug assay. For instance, Cambodia isolate “6” produced some of
the highest overall IC50s to artemisinin, artemether, lumefantrine, dihydroartemisinin,
and mefloquine. Thai isolate “6” was also consistently less susceptible to a majority of
the drugs tested. Cambodia isolate “5” was among the most susceptible parasites and
produced the lowest IC50s to the drugs tested. In addition, when observing IC50 trends
in reference to MFQ, none of the 7 drugs showed a significant positive correlation in
IC50 trends.
Isobologram Assay Data
Thai isolate 6, Cambodia isolate 6, and Thai isolate 18 were chosen for the drug
combination studies based on the fact that they showed the most evidence of resistance to
the drugs when tested individually. Isobolograms depicting the fractional inhibitory
concentrations (FIC) curves were produced using the DPM software (refer to Appx. A).
In order for a drug pair to be considered “synergistic”, the sum of the FICs must be under
0.5. For the drugs tested, only Thai 18 under DHA and MFQ pressure had ∑FIC meeting
this criteria when DHA and MFQ were in a 1:1 ratio of one another. In order for a drug
combination to be considered antagonistic, the FIC sum must be higher than 2 ng/ml
Thai 6, when exposed to QHS and MFQ at a ratio of 1:3 respectively produced an ∑FIC
of 2.320, which indicates a significant antagonistic effect. In addition, Thai 6 treated
with QHS and PIP in a ratio of 1:3 respectively also produced a significant antagonistic
∑FIC of 2.048. The W2 reference clone under similar conditions did not conclusively
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lead to synergism or antagonism, which was expected from previous studies in the Kyle
lab.
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Table 1: IC 50s (ng/ml) of Thai Isolates in the 72 hour SYBR Green Drug Assay

ID
number
3
4
5
6
8
12
13
14
16
18
20
21
22
23
24

AM
1.2
1.1
1.1
0.2
1.6
0.5
1.8
0.5
1.2
2.3
1.8
1.5
1.2
0.7
2.1
1.3

ART ATO DHA
LF
MFQ PIP QHS
1.3 0.1
0.6 157.2 28.4 26.3 4.9
1.2 0.3
0.5
42.4
7.8
8.3
3.9
0.2 0.1
0.5
91.5
7.3 32.7 2.8
0.1 0.1
0.5
32.5
2.3
4.6
1.2
2.5 0.1
1.6 204.9 21.9 20.5 10.0
1.0 0.1
0.9
46.2
4.0 23.2 1.9
0.3 0.1
0.5
51.1 25.5 22.9 4.6
0.2 0.2
0.4 209.1 5.7
8.6
1.6
0.1 0.1
0.5
21.6
3.7 17.6 2.0
0.9 5.1
0.9
3.4
3.4
9.2
5.1
0.8 0.3
1.1 118.8 29.3 22.5 4.4
0.7 0.2
0.6
55.3
5.5 23.0 3.7
0.5 0.2
0.5
15.4
9.8
7.1
2.7
0.3 0.2
0.4
35.9 15.2 2.5
1.4
0.6 0.3
0.8 116.9 20.3 20.9 4.6
0.5 0.2
0.5
53.3
8.2 36.0 3.6
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Table 2: IC 50s (ng/ml) of Cambodia isolates in the 72 hour SYBR Green
Drug Assay

ID

AM

AS

ATO DHA

1
3
5
6
7
8
10
13
16
21
23
25
26
27
32
33
34
42

0.5
0.9
0.3
3.1
0.8
1.4
2.3
1.1
1.5
0.8
1.5
0.6
0.3
0.6
0.6
1.1
1.3
1.0

0.6
0.9
0.3
2.1
1.2
1.0
1.5
0.3
1.3
1.4
0.3
0.1
0.6
0.1
0.6
0.1
0.2
0.1

0.2
0.2
0.1
0.2
0.1
0.2
0.2
0.1
0.2
0.1
0.2
0.1
0.1
0.1
0.3
0.1
0.1
0.2

0.4
0.5
0.1
1.5
0.3
0.8
1.5
1.7
1.2
2.0
0.2
0.1
1.7
0.2
1.1
0.7
0.9
0.3
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LF

MFQ

PIP

QHS

47.5
68.6
29.8
113.6
96.5
25.9
54.2
28.1
10.3
15.6
63.6
11.7
28.0
14.2
114.1
5.4
8.8
13.9

8.1
15.7
5.1
56.0
10.9
8.9
11.5
4.2
3.4
2.4
6.7
2.2
4.5
2.0
8.2
0.8
1.6
1.9

10.1
17.2
16.4
12.4
20.0
15.5
5.2
52.3
17.6
66.4
63.7
18.5
14.3
6.8
29.5
4.7
23.0
19.8

0.7
1.5
0.4
6.1
1.1
2.7
7.7
3.1
4.1
6.6
1.9
1.1
2.2
1.2
2.0
1.9
2.6
1.6

Table 3: IC 50s (ng/ml) of Reference Strains W2, D6 and C2B in the 72
Hour SYBR Green Drug Assay
control
W2
C2B
D6

AM
.58
1.1
1.7

AS
.56
.01
.19

ATO
.19
62.5
.06

DHA
.61
.32
1.74
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LF
6.11
53.78
84.66

MFQ
3.78
4.91
2.44

PIP
28.12
52.24
32.02

QHS
1.48
1.69
2.66

Discussion
Findings
This thesis describes the general resistance trends to 8 commonly used antimalarial drugs in recent P. falciparum isolates from Thailand and Cambodia. It is
important to determine if resistance is occurring early on, in order to devise an efficient
containment plan, which can include, but is not limited to alteration of drug regiments,
education, proper dispersal and formulation of new and improved drugs. As
hypothesized, results from this blinded phenotypic analysis show some trends that
suggest isolates in Southeast Asia as less susceptible to some common ACT drugs. This
is consistent with previous clinical and in vitro studies performed in the past (Noedl,
2008; Khositnithikul, 2008).
In particular, Cambodia isolate 6 and Thai isolate 6 were consistently less
susceptible to the majority of drugs tested, in reference to the other isolates tested, as well
as in comparison to the positive controls, C2b, D6 and W2 (refer to appendix B for
details). Atovaquone was the only drug to which all of the isolates (with the exception of
Thai isolate 13) were consistently susceptible. Again, molecular markers testing should
be conducted on Thai 13 in order to determine if a point mutation in Cytochrome B is
indeed occurring, a key sign of atovaquone resistance ( Khositnithikul,2008).
Drug combination assay studies revealed some unexpected trends towards
antagonism for several ACT combinations. An example of this was when Thai 6 was
exposed to the 1 part QHS and 3 part MFQ drug combination (∑FIC=2.048), as well as
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when exposed to the 3 QHS part and 1 part PIP drug combination (∑FIC=2.32). Trends
for some synergism in the drug combination responses were also observed with this
assay, the most significant one being Thai 18 when incubated with 1 part DHA to 1 part
MFQ (∑FIC=.362).
These blinded results should be validated via other methods. The isolate data on
drug susceptibility still needs to be tied back to original parasitemia and specific location
to examine the trends more closely. The results could be biased in that the majority of
the isolates assayed may have originated from isolates with higher original parasite load.
The isolates that did not grow successfully in the lab must be attempted to grow again so
that one is not selecting and testing for a severe infection only. Also, it is possible that
these isolates already contained other types of drugs and although a thorough wash
protocol was used, previous drug pressure could have also negatively affected the
accuracy of our results when selecting for a particular drug.
Strengths and Weaknesses
The use of the SYBR Green assay has many advantages opposed to other
conventional ways to evaluate drug effectiveness and ultimately drug resistance trends.
For instance, lab personnel safety and clean up is a lot easier than a radioisotope assay. It
is faster to carry out than an ELISA, which requires multiple washing steps, and the
materials needed to complete the assay are easier to obtain. Finally, the SYBR Green
assay is more consistent and easier than the micro test (morphology based), which
requires slides of each of the 96 well plates before a conclusion could be made (Bacon,
2006). Unfortunately, there are many variables in the assay that could negatively affect
the accuracy of the results obtained. For instance, slight alterations in parasite
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parasitemia, hematocrit, and plasma lots could significantly alter IC50s obtained from all
of the assay formats, including SYBR green.
Testing drug combinations that have major structural and functional differences
can also affect the accuracy of the data obtained. For instance, if the improper ratio of
drugs is used in a drug assay and one drug has a much different dose response profile, the
∑FICs could become skewed. Also, FICs can vary based on parasite strain and
parasitemia, and since this is a blinded study, it is difficult to come to a solid conclusion
regarding drug-drug interactions. Further information and testing will need to be done in
order to validate the assumptions made regarding the drug combinations.
The data in the drug assays provide a phenotype that characterizes the drug
response. These phenotypes will be useful to identify putative genetic markers of
resistance, such as SNPs or amplifications. If the mechanism of resistance is known for
artemisinin and its derivatives, one can then test whether or not the same mechanism is
occurring in a particular isolate of interest.
Future study plans
This study is the initial step in characterizing resistance trends in these particular
isolates. Data for these isolates will be compared to fresh, ex vivo in vitro drug
susceptibility data conducted at the clinical field sites. Isolates that did not successfully
grow during this experiment will be attempted to be grown once again. Also, isolates
showing decreased susceptibility to ACTs will also have further tests performed. SNP
studies, gene amplifications, as well as sequencing entire genomes to figure out resistance
mechanisms will occur in the future at the University of Maryland. Only then, will the
real story of current ACT resistance be fully understood.
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Appendix A

Cambodia isolate 6 QHS(97) MFQ (99)

Cambodia isolate 6 QHS(97) PIP (444)
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Appendix A (continued)

Thai isolate 6 QHS(97) MFQ (99)

Thai 6 QHS(97) PIP(444)
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Appendix A (continued)
Thai 18 DHA (414) MFQ (99)

Thai isolate 18 pip(444) DHA(414)
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Appendix A (continued)
W2 control QHS(97) PIP(444)

W2 QHS (97) and MFQ (99)
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Appendix A (continued)
W2 DHA (414) PIP (444)
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Appendix B
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Appendix B continued
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Appendix B continued
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Appendix B continued
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Appendix B continued
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Appendix B continued
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Appendix B continued
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